top of page
LabyRx has developed unconventional cancer therapeutics directed against a novel cancer target. Our unique target is called Labyrinthin*.
Our lead product, LabVax, is a Labyrinthin-derived synthetic peptide vaccine that recruits the body's immune cells to attack adenocarcinomas cancers, which represent approximately 40% of all cancers and over 60% of all cancer deaths.
To bring novel therapies harnessing our body's own immune system to treat patients suffering from a wide range of adenocarcinoma cancers.
bottom of page